Unlock instant, AI-driven research and patent intelligence for your innovation.
Novel tricyclic compound as irak4 inhibitor
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A cyclic compound, chemical formula technology, applied in the field of new tricyclic compounds as IRAK4 inhibitors, can solve the problems of inability to greatly improve the disease, high cost, and achieve excellent inhibitory activity.
Pending Publication Date: 2021-08-06
KOREA RES INST OF CHEM TECH
View PDF16 Cites 2 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Belimumab (Benlysta: belimumab, GSK, 2010), the first new drug for lupus, is an antibody injection that inhibits abnormal B lymphocytes by inhibiting the binding of B-cell receptors of BlyS (BAFF), but it is not only expensive, Also has the problem of not being able to substantially improve the disease
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
manufacture example 16
[0132] [Production Example 1] Production of 6-bromo-4-chloro-9H-pyrimido[4,5-b]indole (compound 4a)
[0133]
[0134] Step 1. Production of compound 2a
[0135] After compound 1a (36 g, 143 mmol) was dissolved in dichloromethane (300 ml), triethylamine (40 mL, 287 mmol) was added, and trifluoroacetic anhydride (30 mL, 216 mmol) was added slowly at 0°C. Wash with distilled water (2×300mL) after the reaction finishes, then wash with sodiumsulfate (Na 2 SO 4 ) to remove moisture and concentrate under reduced pressure to obtain 50 g of trifluoroacetamide (trifluoroacetamide) derivatives.
[0136] Dissolve the trifluoroacetamide derivative in DMSO (dimethyl sulfoxide)-distilled water (1:1; 280 mL), and add methyl cyanoacetate (15 mL, 170 mmol), DL-proline (3.3 g, 18.8 mmol ), K 2 CO 3 (40g, 289mmol), CuI (2.73g, 14.3mmol), and stirred at 60°C for 14 hours. After cooling the reactant to room temperature, the solid was filtered, washed with methanol (2×100 mL), and the filt...
manufacture example 2
[0144] [Production Example 2] Production of ethyl 4-chloro-9H-pyrimido[4,5-b]indole-6-carboxylic acid methyl ester (compound 4b)
[0145]
[0146] Compound 4b was produced from compound 1b in three steps in the same manner as in Production Example 1 above.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or tumors, containing, as an active ingredient, a tricyclic compound represented by the following formula 1 or a pharmaceutically acceptable salt thereof, and a health food composition for preventing or alleviating autoimmune diseases or tumors, containing the tricyclic compound as an active ingredient. [Chemical formula 1] A tricyclic compound represented by chemical formula 1 of the present invention has an excellent inhibitory activity against IRAK4, and thus can be effectively used in the prevention, treatment, or alleviation of autoimmune diseases or tumors.
Description
technical field [0001] The present invention relates to a novel tricyclic compound as an IRAK4 inhibitor, a pharmaceutical composition for preventing or treating autoimmune diseases or tumors containing the tricyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient, And a health food composition containing the ternary compound as an active ingredient for preventing or improving autoimmune diseases or tumors. Background technique [0002] IRAK4 (Interleukin-1 receptor (IL-1R) associated kinase 4) acts as a mediator to send Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signals into cells in bone marrow cells and lymphocytes It is the main phosphorylase that is transmitted, and it is being actively studied as a therapeutic target for rare immune diseases such as systemic lupus erythematosus (SLE) and lymphoma (Current Topics in Medicinal Chemistry, 2009, 9, 724-737) . [0003] Lupus is an autoimmune disease of unknown cause, if 4 or...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.